| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Articles in PresS, published online ahead of print September 24, 2002
Am J Physiol Endocrinol Metab, 10.1152/ajpendo.00363.2002
Submitted on August 15, 2002
Accepted on September 18, 2002
1 Department of Medicine, Radiology and Biokinesiology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
2 Department of Endocrinology, Metabolism, and Molecular Medicinecine, Charles Drew University of Medicine, Los Angeles, CA, USA
* To whom correspondence should be addressed. E-mail: fsattler{at}usc.edu.
To determine whether oxymetholone increases lean body mass (LBM) and skeletal muscle strength in older persons, 31 men 65-80 years of age were randomized to placebo (Group 1), 50-mg (Group 2) or 100-mg (Group 3) daily for 12 weeks. For the three groups, total LBM increased by 0.0±0.6, 3.3±1.2 (p<0.001) and 4.2±2.4 kg (p<0.001), respectively. Trunk fat decreased by 0.2±0.4, 1.7±1.0 (p=0.018) and 2.2±0.9 kg (p=0.005) in groups 1, 2 and 3, respectively. Relative increases in 1-repetition maximum (1-RM) strength for biaxial chest press of 8.2±9.2% and 13.9±8.1% in the two active treatment groups were significantly different than the change (-0.8±4.3)for the placebo group (p<0.03). For lat pull-down, 1-RM changed by -0.6±8.3%, 8.8±15.1% and 18.4±21.0 for the groups, respectively (1-way ANOVA; p=0.019). The pattern of changes among the groups for LBM and upper body strength suggested that changes might be related to dose. ALT increased by 72±67 U/L in Group 3 (p<0.001) and HDL cholesterol decreased by -19±9 and -23±18 mg/dL in groups 2 and 3, respectively (p=0.04 and p=0.008). Thus, oxymetholone improved LBM and maximal voluntary muscle strength, and decreased fat mass in older men.
This article has been cited by other articles:
|
|
 |
|
  E. T. Schroeder, Y. Wang, C. Castaneda-Sceppa, G. Cloutier, A. F. Vallejo, M. Kawakubo, N. E. Jensky, S. Coomber, S. P. Azen, and F. R. Sattler Reliability of Maximal Voluntary Muscle Strength and Power Testing in Older Men J. Gerontol. A Biol. Sci. Med. Sci., May 1, 2007; 62(5): 543 - 549. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A.-M. Axell, H. E. MacLean, D. R. Plant, L. J. Harcourt, J. A. Davis, M. Jimenez, D. J. Handelsman, G. S. Lynch, and J. D. Zajac Continuous testosterone administration prevents skeletal muscle atrophy and enhances resistance to fatigue in orchidectomized male mice Am J Physiol Endocrinol Metab, September 1, 2006; 291(3): E506 - E516. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Chen, J. D Zajac, and H. E MacLean Androgen regulation of satellite cell function J. Endocrinol., July 1, 2005; 186(1): 21 - 31. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. T. Page, K. L. Herbst, J. K. Amory, A. D. Coviello, B. D. Anawalt, A. M. Matsumoto, and W. J. Bremner Testosterone Administration Suppresses Adiponectin Levels in Men J Androl, January 1, 2005; 26(1): 85 - 92. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. T. Schroeder, M. Terk, and F. R. Sattler Androgen therapy improves muscle mass and strength but not muscle quality: results from two studies Am J Physiol Endocrinol Metab, July 1, 2003; 285(1): E16 - E24. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Visit Other APS Journals Online |
